Immune checkpoint inhibitors in malignant pleural mesothelioma

The Lancet Oncology

Volumn 18, Issue 5, 2017, Pages 559-561

  Ceresoli, Giovanni Luca ^a   Mantovani, Alberto ^b  

^a Humanitas Gavazzeni Hospital   (Italy)

^b HUMANITAS UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PEMBROLIZUMAB; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB;

CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; HUMAN; MUTATIONAL LOAD; NATURAL KILLER CELL; NOTE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PROGRESSION FREE SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE; LUNG TUMOR; MESOTHELIOMA; PLEURA TUMOR;

HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 85018742787     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30191-2     Document Type: Note

References (10)

1. 1 Kindler, HL, Scherpereel, A, Calabrò, L, et al. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): results from the global, double-blind, placebo-controlled DETERMINE study. Proc Am Soc Clin Oncol, 34, 2016 abstr 8502.
2. 2 Hassan, R, Thomas, A, Patel, MR, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression. Proc Am Soc Clin Oncol, 34, 2016 abstr 8503.
3. 3 Quispel-Janssen, J, Zago, G, Schouten, R, et al. A phase II study of nivolumab in malignant pleural mesothelioma (NIVOMES) with translational research biopsies. J Thor Oncol, 12(suppl. 1), 2017 OA13.01.
4. 4 Kindler, HL, Karrison, T, Tan, YHC, et al. Phase II trial of pembrolizumab in patients with malignant mesothelioma: interim results. J Thor Oncol, 12(suppl. 1), 2017 OA13.02.
5. 5 Alley, EW, Lopez, J, Santoro, A, et al. Clinical safety and efficacy of pembrolizumab in patients with malignant pleural mesothelioma: preliminary results from the phase 1b, non-randomised, open-label KEYNOTE-028 trial. Lancet Oncol 18 (2017), 623–630.
6. 6 Bueno, R, Stawiski, EW, Goldstein, LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48 (2016), 407–416.
7. 7 Yamagishi, T, Fujimoto, N, Nishi, H, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma. Lung Cancer 90 (2015), 111–117.
8. 8 Pesce, S, Greppi, M, Tabellini, G, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol 139 (2017), 335–346.
9. 9 Mantovani, A, Marchesi, F, Malesci, A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol, 2017, 10.1038/nrclinonc.2016.217 published online Jan 24.
10. 10 Bottai, G, Raschioni, G, Székely, B, et al. AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients. NPJ Breast Cancer, 2, 2016, 16033.